Enorama Pharmas preferential rights issue oversubscribed

27 November 2018

"A few days after the announcement, we would like to reflect on the strong outcome and the great interest.

For Enorama, it is incredibly exciting to see that so many are convinced that there is a strong future potential in the Company. More shares were requested than what the offer included. We are extremely pleased with the result and the great interest shown to us. We also want to thank all shareholders for the commitment you show by asking interesting questions and following us closely", says Mats Rönngard, CEO at Enorama Pharma.

Read the full CEO comment in Swedish